Bio Rad Laboratories Inc
NYSE:BIO.B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bio Rad Laboratories Inc
NYSE:BIO.B
|
US |
|
SBC Medical Group Holdings Inc
NASDAQ:SBC
|
US |
|
Nile Ltd
BSE:530129
|
IN |
|
Bancorp 34 Inc
OTC:BCTF
|
US |
|
LXRandCo Inc
TSX:LXR
|
CA |
|
Dwarikesh Sugar Industries Ltd
NSE:DWARKESH
|
IN |
|
Solusi Bangun Indonesia Tbk PT
IDX:SMCB
|
ID |
|
Hochschild Mining PLC
LSE:HOC
|
UK |
|
DecisionPoint Systems Inc
F:RS7
|
US |
|
Japan Display Inc
TSE:6740
|
JP |
Wall Street
Price Targets
BIO.B Price Targets Summary
Bio Rad Laboratories Inc
According to Wall Street analysts, the average 1-year price target for
BIO.B
is 342.51 USD
with a low forecast of 283.47 USD and a high forecast of 394.68 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is BIO.B's stock price target?
Price Target
342.51
USD
According to Wall Street analysts, the average 1-year price target for
BIO.B
is 342.51 USD
with a low forecast of 283.47 USD and a high forecast of 394.68 USD.
What is Bio Rad Laboratories Inc's Revenue forecast?
Projected CAGR
3%
For the last 14 years the
compound annual growth rate for
Bio Rad Laboratories Inc's revenue is
2%.
The projected
CAGR
for the next 3 years is
3%.
What is Bio Rad Laboratories Inc's Operating Income forecast?
Projected CAGR
11%
For the last 14 years the
compound annual growth rate for
Bio Rad Laboratories Inc's operating income is
-1%.
The projected
CAGR
for the next 3 years is
11%.
What is Bio Rad Laboratories Inc's Net Income forecast?
Projected CAGR
-24%
For the last 14 years the
compound annual growth rate for
Bio Rad Laboratories Inc's net income is
11%.
The projected
CAGR
for the next 3 years is
-24%.
